[The historical synchronicities of the Eli Lilly Canada Chair on schizophrenia research]

Stéphane Potvin1, Emmanuel Stip1

  • 1Université de Montréal, Québec, Canada.

Sante Mentale Au Quebec
|December 10, 2024
PubMed

Insights

This study reviews 15 years of schizophrenia research, highlighting key findings in cognition, neuroimaging, and antipsychotics. External factors significantly influenced the research trajectory, impacting psychosis understanding.

Area of Science:

  • Psychiatry and Neuroscience
  • Bibliometrics
  • History of Science

Background:

  • The Eli Lilly Canada Chair on schizophrenia research was established in 2004.
  • Funded by Eli Lilly and several Montreal-based institutions.
  • The chair aimed to advance schizophrenia research.

Purpose of the Study:

  • To provide a historical overview of the scientific activities of the Chair since its inception.
  • To analyze the research output and impact using a bibliometric approach.
  • To interpret the scientific work from an externalist perspective.

Main Methods:

  • Conducted a PubMed search for articles by Chair holders since 2004.
  • Utilized Google Scholar to count citations for each article.
  • Identified and counted main themes within the published articles.

Main Results:

  • Published 295 scientific articles cited 12,892 times.
  • Key themes: cognition, neuroimaging, antipsychotics, addiction, psychosocial interventions, treatment resistance.
  • Influential articles addressed inflammation, sleep, aberrant salience, language lateralization, and antipsychotics/COVID-19 links.

Conclusions:

  • Schizophrenia research evolution influenced by external factors like antipsychotic commercialization and neuroimaging democratization.
  • Cannabis legalization and digital health also impacted research directions.
  • Reflections on psychosis concept and research trends counter to social currents.